(E)-Akt inhibitor-IV(Synonyms: (E)-AKTIV)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

(E)-Akt inhibitor-IV (Synonyms: (E)-AKTIV) 纯度: 98.61%

(E)-Akt inhibitor-IV ((E)-AKTIV) 是一种 PI3K-Akt 抑制剂,具有显著的细胞毒性。

(E)-Akt inhibitor-IV(Synonyms: (E)-AKTIV)

(E)-Akt inhibitor-IV Chemical Structure

CAS No. : 959841-49-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥2030 In-stock
5 mg ¥1500 In-stock
10 mg ¥2500 In-stock
25 mg ¥5500 In-stock
50 mg ¥8500 In-stock
100 mg ¥13500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

(E)-Akt inhibitor-IV 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

(E)-Akt inhibitor-IV ((E)-AKTIV) is a PI3K-Akt inhibitor, with potent cytotoxic[1].

IC50 & Target

Akt[1]

体外研究
(In Vitro)

(E)-Akt inhibitor-IV (compound 7) exhibits average GI20 of 0.04 μM on four cell lines (MDA-MB468 cells, MDA-MB231 cells, MCF7 cells and 184B5 cells)[1].
(E)-Akt inhibitor-IV shows little effects on the growth of 184B5 non-cancer cells at the average GI20 doses[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

614.54

Formula

C31H27IN4S

CAS 号

959841-49-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 50 mg/mL (81.36 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6272 mL 8.1362 mL 16.2723 mL
5 mM 0.3254 mL 1.6272 mL 3.2545 mL
10 mM 0.1627 mL 0.8136 mL 1.6272 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2 mg/mL (3.25 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (3.25 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Changkun Hu, et al. A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells. Eur J Med Chem. 2010 Feb;45(2):705-9.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Polygalacin D

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Polygalacin D  纯度: 99.30%

Polygalacin D (PGD) 是从桔梗 Platycodon grandiflorum 中分离的具有抗癌和抗增殖特性的生物活性化合物。 Polygalacin D 抑制 IAP 蛋白家族的表达,包括存活蛋白,cIAP-1 和 cIAP-2 蛋白,并通过抑制 GSK3β,Akt 的磷酸化和PI3K 的表达来阻断 PI3K/Akt 途径。Polygalacin D 通过 PI3K/Akt 途径诱导凋亡 (apoptosis)。

Polygalacin D

Polygalacin D Chemical Structure

CAS No. : 66663-91-0

规格 价格 是否有货 数量
1 mg ¥1520 In-stock
5 mg ¥4570 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Polygalacin D 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Glycoside Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library

生物活性

Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum (Jacq.) with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis[1]

IC50 & Target

IC50: IAP[1]

体外研究
(In Vitro)

Polygalacin D (0-40 µM; 48 hours) inhibits cell proliferation with IC50s of 26.49 µM in the A549 cells and 20.52 µM in the H460 cells[1].
Polygalacin D (0-20 µM; 48 hours) increases the proportion of early and late apoptotic cells, and nuclear condensation is observed in A549 and H460 cells[1].
Polygalacin D (0-20 µM; 48 hours) may exerts its apoptotic effects by regulating the apoptotic proteins and the IAP family of proteins in A549 and H460 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: A549 and H460 cancer cell lines
Concentration: 10 µM, 20 µM, 40µM
Incubation Time: 48 hours
Result: Inhibited the proliferation of NSCLC cell lines.

Apoptosis Analysis[1]

Cell Line: A549 and H460 cancer cell lines
Concentration: 10 µM, 20 µM
Incubation Time: 48 hours
Result: Induced apoptosis of NSCLC cell lines.

Western Blot Analysis[1]

Cell Line: A549 and H460 cancer cell lines
Concentration: 10 µM, 20 µM
Incubation Time: 48 hours
Result: Decreased survivin, c-IAP-1 and c-IAP-2 expression.

分子量

1209.32

Formula

C57H92O27

CAS 号

66663-91-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : 100 mg/mL (82.69 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.8269 mL 4.1346 mL 8.2691 mL
5 mM 0.1654 mL 0.8269 mL 1.6538 mL
10 mM 0.0827 mL 0.4135 mL 0.8269 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.07 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.07 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.07 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Seo YS, et al. Polygalacin D induces apoptosis and cell cycle arrest via the PI3K/Akt pathway in non-small cell lung cancer. Oncol Rep. 2018 Apr;39(4):1702-1710.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-1  纯度: 98.41%

AKT-IN-1 是一种变构 AKT 抑制剂,IC50 为 1.042 μM。

AKT-IN-1

AKT-IN-1 Chemical Structure

CAS No. : 1357158-81-6

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1889 In-stock
5 mg ¥2500 In-stock
10 mg ¥4500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

AKT-IN-1 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

AKT-IN-1 is an allosteric AKT inhibitor with an IC50 of 1.042 μM.

IC50 & Target

IC50: 1.042 μM (AKT)[1]

体外研究
(In Vitro)

AKT-IN-1 is able to potently inhibit phosphorylation of AKT in cells at both Thr308 and Ser473, with IC50s of 0.422 and 0.322 μM, respectively. AKT-IN-1 inhibits the phosphorylation of ribosomal protein S6, a downstream effector of the PI3K-AKT pathway. AKT-IN-1 potently inhibits the phosphorylation of PRAS40[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The effects of AKT-IN-1 (Compound 26) in vivo are characterized by measuring the pharmacodynamic activity of AKT-IN-1 in a BT474c breast adenocarcinoma xenograft model. Following acute doses of 100 and 200 mg/kg, AKT-IN-1 potently inhibits the phosphorylation of its downstream substrate GSK3β as well as the phosphorylation of AKT (Ser473), with a potency consistent with its pharmacokinetic profile. The in vivo activity of AKT-IN-1 is further characterized by measuring the effects on the growth of tumor cell xenografts. Continuous (daily) oral dosing of AKT-IN-1 (100 and 200 mg/kg) to nude mice bearing BT474c breast adenocarcinoma xenografts results in inhibition of tumor growth in a dose-dependent manner. When dosed at 200 mg/kg daily, AKT-IN-1 causes significant tumor growth inhibition[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

343.42

Formula

C22H21N3O

CAS 号

1357158-81-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 75 mg/mL (218.39 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.9119 mL 14.5594 mL 29.1189 mL
5 mM 0.5824 mL 2.9119 mL 5.8238 mL
10 mM 0.2912 mL 1.4559 mL 2.9119 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.28 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.28 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.28 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Kettle JG, et al. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT. J Med Chem. 2012 Feb 9;55(3):1261-73.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PF-AKT400(Synonyms: AKT protein kinase inhibitor)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PF-AKT400 (Synonyms: AKT protein kinase inhibitor) 纯度: ≥98.0%

PF-AKT400 是一种有效的, ATP 竞争性的选择性 Akt 抑制剂,对 PKBα (IC50=0.5 nM) 的选择性比 PKA (IC50=450 nM) 高 900 倍。

PF-AKT400(Synonyms: AKT protein kinase inhibitor)

PF-AKT400 Chemical Structure

CAS No. : 1004990-28-6

规格 价格 是否有货 数量
5 mg ¥2900 In-stock
10 mg ¥4200 In-stock
50 mg ¥12000 In-stock
100 mg ¥18000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

PF-AKT400 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Targeted Diversity Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

PF-AKT400 is a broadly selective, potent, ATP-competitive Akt inhibitor, displays 900-fold greater selectivity for PKBα (IC50=0.5 nM) than PKA (IC50=450 nM).

IC50 & Target[1]

PKBα

0.5 nM (IC50)

PKA

450 nM (IC50)

体外研究
(In Vitro)

PF-AKT400 (Compound 42) provides significantly enhanced selectivity for Akt relative to earlier leads such as spiroindoline 2. Free IC50 and EC50 values are estimated for phospho-S6 reduction (110 nM) and Akt hyperphosphorylation (216 nM), respectively. These values corresponded well to the cellular IC50 for PF-AKT400 in U87 cells measuring p-GSK-3α (310 nM)[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

PF-AKT400 is subsequently evaluated for modulation of Akt in tumors and in multiple in vivo mouse models of antitumor efficacy. It is active in a PC3 prostate carcinoma xenograft experiment, with 75% TGI observed at 100 mg/kg b.i.d. dosing for 10 days. In a colorectal carcinoma (Colo205) xenograft study, PF-AKT400 produces 60% TGI at 150 mg/kg b.i.d. after 10 days. Most intriguingly, in combination with Rapamycin (10 mg/kg, ip), 75 mg/kg b.i.d. (10 days) of PF-AKT400 results in 98% TGI in an additional PC3 prostate carcinoma xenograft study compared to 56% TGI and 66% TGI with PF-AKT400 and Rapamycin as single agents. To define the in vivo potency of PF-AKT400 (Compound 42) in the PC3 xenograft model, oral administration of 25, 75, and 100 mg/kg PF-AKT400 is performed with blood and tumor sampling over time. Immunoblot analysis of detergent-soluble extracts derived from PC3 tumors shows a significant reduction of S6 phosphorylation, and hyperphosphorylation of Akt upon treatment at doses that produced significant tumor growth inhibition. Plasma drug concentrations peak rapidly after oral administration of doses between 25-100 mg/kg (Tmax=0.5 h). Peak PD responses of phospho-S6 and phospho-Akt are observed at approximately 2-4h and 1h post-administration of PF-AKT400, respectively. The time-course of PD marker response is well described by a PK/PD model at doses that ranged from no efficacy (25 mg/kg) to maximal efficacy (100 mg/kg)[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

400.43

Formula

C20H22F2N6O

CAS 号

1004990-28-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (249.73 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4973 mL 12.4866 mL 24.9732 mL
5 mM 0.4995 mL 2.4973 mL 4.9946 mL
10 mM 0.2497 mL 1.2487 mL 2.4973 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.24 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Chen SF, et al. Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. J Mol Model. 2013 Nov;19(11):5097-5112.

    [2]. Freeman-Cook KD, et al. Design of selective, ATP-competitive inhibitors of Akt. J Med Chem. 2010 Jun 24;53(12):4615-4622.

Kinase Assay
[2]

A fluorescence polarization IMAP type assay is used. An amount of 15 μL of diluted PF-AKT400 (Compound 42) in DMSO is mixed with 60 μL of reaction buffer (10 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.01% Triton-X100, 1 mM DTT). Then 5 μL of the compound/buffer mixture, 10 μL of a solution containing 4 μM ATP and 40 nM fluorescent-labeled Crosstide (Tamara-labeled GRPRTSSFAEG peptide), and 5 μL of Akt1 protein (lacking the pleckstrin homology (PH) domain, containing an Asp at position 473, and prephosphorylated at Thr 308) in reaction buffer are combined. After a 90 min incubation, IMAP beads are added and plates are read (lamp filter, 544 nm; emission filter, 615 nm). The same procedure can be applied to full length Akt1 to provide similar results. All IC50 values are the geometric mean of at least n=2 determinations[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice[2]
Studies to describe the PK/PD relationship for PF-AKT400 are performed in male SCID/Beige mice bearing subcutaneous PC3 prostate carcinoma xenografts. Once tumors reach about ~300mm3 in size, PF-AKT400 is formulated in 0.5% methylcellulose vehicle and administered orally to 3 mice per dose group. Plasma and tumors are harvested over time, tumor lysates prepared, and the levels of phospho S6 reduction and phospho Akt induction are evaluated by immunoblot.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Chen SF, et al. Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. J Mol Model. 2013 Nov;19(11):5097-5112.

    [2]. Freeman-Cook KD, et al. Design of selective, ATP-competitive inhibitors of Akt. J Med Chem. 2010 Jun 24;53(12):4615-4622.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-6

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-6  纯度: 99.51%

AKT-IN-6 (Example 13) 是一种有效的 AKT 抑制剂。AKT-IN-6抑制 Akt1、Akt2 和 Akt3, IC50s 分别 < 500nM,来自专利WO201305615A1。

AKT-IN-6

AKT-IN-6 Chemical Structure

CAS No. : 1430056-54-4

规格 价格 是否有货 数量
5 mg ¥1200 In-stock
10 mg ¥2100 In-stock
25 mg ¥4200 In-stock
50 mg ¥7200 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

AKT-IN-6 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Diabetes Related Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Glucose Metabolism Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).

IC50 & Target

Akt1

 

Akt2

 

Akt3

 

体外研究
(In Vitro)

Akt is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli. Aberrant loss or gain of Akt activation underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

389.43

Formula

C22H20FN5O

CAS 号

1430056-54-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (320.98 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5679 mL 12.8393 mL 25.6786 mL
5 mM 0.5136 mL 2.5679 mL 5.1357 mL
10 mM 0.2568 mL 1.2839 mL 2.5679 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.34 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.34 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.34 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Taisheng Huang; et al.Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors. WO2013056015A1.

    [2]. Manning BD, et al. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-1274.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-3

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-3 

AKT-IN-3 (compound E22) 是一种有效、口服的低 hERG 阻断 Akt 抑制剂,对 Akt1、Akt2 和 Akt3 作用的 IC50 值分别为 1.4 nM、1.2 nM 和 1.7 nM。AKT-IN-3 (compound E22) 对其他 AGC 家族激酶也有较好的抑制活性,如 PKA、PKC、ROCK1、RSK1、P70S6K、SGK。AKT-IN-3 (compound E22) 能诱导癌细胞凋亡,抑制癌细胞的转移。

AKT-IN-3

AKT-IN-3 Chemical Structure

CAS No. : 2374740-21-1

规格 价格 是否有货
5 mg ¥26500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells[1].

IC50 & Target[1]

Akt1

1.4 nM (IC50)

Akt2

1.2 nM (IC50)

Akt3

1.7 nM (IC50)

PKA

0.3 nM (IC50)

P70S6K

8.9 (IC50)

分子量

526.36

Formula

C23H23Cl2F2N5O3

CAS 号

2374740-21-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Dong X, et al. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem. 2019 Aug 8;62(15):7264-7288.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-5

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-5 

AKT-IN-5 (Example 8) 是一种 Akt 抑制剂,对 Akt1Akt2IC50 值分别为 450 nM 和 400 nM。

AKT-IN-5

AKT-IN-5 Chemical Structure

CAS No. : 1402608-05-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-5 (Example 8) is a Akt inhibitor with IC50 values of 450 nM and 400 nM for Akt1 and Akt2, respectively[1].

IC50 & Target[1]

Akt1

450 nM (IC50)

Akt2

400 nM (IC50)

分子量

384.43

Formula

C23H20N4O2

CAS 号

1402608-05-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Lars BÄRFACKER, et al. Imidazopyridazines as akt kinase inhibitors. WO2012136776A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-5

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-5 

AKT-IN-5 (Example 8) 是一种 Akt 抑制剂,对 Akt1Akt2IC50 值分别为 450 nM 和 400 nM。

AKT-IN-5

AKT-IN-5 Chemical Structure

CAS No. : 1402608-05-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-5 (Example 8) is a Akt inhibitor with IC50 values of 450 nM and 400 nM for Akt1 and Akt2, respectively[1].

IC50 & Target[1]

Akt1

450 nM (IC50)

Akt2

400 nM (IC50)

分子量

384.43

Formula

C23H20N4O2

CAS 号

1402608-05-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Lars BÄRFACKER, et al. Imidazopyridazines as akt kinase inhibitors. WO2012136776A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-5

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-5 

AKT-IN-5 (Example 8) 是一种 Akt 抑制剂,对 Akt1Akt2IC50 值分别为 450 nM 和 400 nM。

AKT-IN-5

AKT-IN-5 Chemical Structure

CAS No. : 1402608-05-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-5 (Example 8) is a Akt inhibitor with IC50 values of 450 nM and 400 nM for Akt1 and Akt2, respectively[1].

IC50 & Target[1]

Akt1

450 nM (IC50)

Akt2

400 nM (IC50)

分子量

384.43

Formula

C23H20N4O2

CAS 号

1402608-05-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Lars BÄRFACKER, et al. Imidazopyridazines as akt kinase inhibitors. WO2012136776A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-11

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-11 

AKT-IN-11 是抗人肝癌Bel-7402细胞株最有效的抗菌剂之一,其IC501.15μM。

AKT-IN-11

AKT-IN-11 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-11 is one of the most effective antibacterial agents against human hepatoma BEL-7402 cell line with an IC50 value of 1.15μM.

IC50 & Target

AKT,ERK

1.15 μM (IC50)

分子量

521.96

Formula

C27H27ClF3NO4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Hai Y,et al. Semisynthesis and biological evaluation of (+)-sclerotiorin derivatives as antitumor agents for the treatment of hepatocellular carcinoma. Eur J Med Chem. 2022 Feb 5;232:114166.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-11

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-11 

AKT-IN-11 是抗人肝癌Bel-7402细胞株最有效的抗菌剂之一,其IC501.15μM。

AKT-IN-11

AKT-IN-11 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-11 is one of the most effective antibacterial agents against human hepatoma BEL-7402 cell line with an IC50 value of 1.15μM.

IC50 & Target

AKT,ERK

1.15 μM (IC50)

分子量

521.96

Formula

C27H27ClF3NO4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Hai Y,et al. Semisynthesis and biological evaluation of (+)-sclerotiorin derivatives as antitumor agents for the treatment of hepatocellular carcinoma. Eur J Med Chem. 2022 Feb 5;232:114166.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-11

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-11 

AKT-IN-11 是抗人肝癌Bel-7402细胞株最有效的抗菌剂之一,其IC501.15μM。

AKT-IN-11

AKT-IN-11 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-11 is one of the most effective antibacterial agents against human hepatoma BEL-7402 cell line with an IC50 value of 1.15μM.

IC50 & Target

AKT,ERK

1.15 μM (IC50)

分子量

521.96

Formula

C27H27ClF3NO4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Hai Y,et al. Semisynthesis and biological evaluation of (+)-sclerotiorin derivatives as antitumor agents for the treatment of hepatocellular carcinoma. Eur J Med Chem. 2022 Feb 5;232:114166.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

APN/AKT-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

APN/AKT-IN-1 

APN/AKT-IN-1 是一种有效的 APN 和 AKT 双重抑制剂,IC50s 分别为 0.21 和 0.27 μM。APN/AKT-IN-1 可有效抑制 AKT 的胞内底物GSK3β的磷酸化。

APN/AKT-IN-1

APN/AKT-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT[1].

分子量

389.45

Formula

C18H27N7O3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Liu Q, et al. Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors. ACS Med Chem Lett. 2021;12(12):1932-1941.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

APN/AKT-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

APN/AKT-IN-1 

APN/AKT-IN-1 是一种有效的 APN 和 AKT 双重抑制剂,IC50s 分别为 0.21 和 0.27 μM。APN/AKT-IN-1 可有效抑制 AKT 的胞内底物GSK3β的磷酸化。

APN/AKT-IN-1

APN/AKT-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT[1].

分子量

389.45

Formula

C18H27N7O3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Liu Q, et al. Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors. ACS Med Chem Lett. 2021;12(12):1932-1941.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

APN/AKT-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

APN/AKT-IN-1 

APN/AKT-IN-1 是一种有效的 APN 和 AKT 双重抑制剂,IC50s 分别为 0.21 和 0.27 μM。APN/AKT-IN-1 可有效抑制 AKT 的胞内底物GSK3β的磷酸化。

APN/AKT-IN-1

APN/AKT-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT[1].

分子量

389.45

Formula

C18H27N7O3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Liu Q, et al. Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors. ACS Med Chem Lett. 2021;12(12):1932-1941.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-9

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-9 

AKT-IN-9 是一种有效的 AKT 抑制剂。蛋白激酶 B (PKB,也称为 AKT) 是细胞中 PI3K/AKT/mTOR 信号传导的核心,其功能对细胞生长、存活、分化和代谢很重要。AKT-IN-9 具有研究乳腺癌和前列腺癌的潜力 (摘自专利 WO2021185238A1,化合物 1)。

AKT-IN-9

AKT-IN-9 Chemical Structure

CAS No. : 2709045-53-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1)[1].

IC50 & Target

AKT[1]

分子量

452.98

Formula

C24H29ClN6O

CAS 号

2709045-53-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Xin Li, et al. Thickened dicyclic derivatives, their preparation methods and their application in medicine. Patent WO2021185238A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-10

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-10 

AKT-IN-10 是一种有效的 AKT 抑制剂。蛋白激酶 B (PKB,也称为 AKT) 是细胞中 PI3K/AKT/mTOR 信号传导的核心,其功能对细胞生长、存活、分化和代谢很重要。AKT-IN-10 具有研究乳腺癌和前列腺癌的潜力 (摘自专利 WO2021185238A1,化合物 4)。

AKT-IN-10

AKT-IN-10 Chemical Structure

CAS No. : 2709045-56-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4)[1].

IC50 & Target

AKT[1]

分子量

484.03

Formula

C26H34ClN5O2

CAS 号

2709045-56-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Xin Li, et al. Thickened dicyclic derivatives, their preparation methods and their application in medicine. Patent WO2021185238A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-9

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-9 

AKT-IN-9 是一种有效的 AKT 抑制剂。蛋白激酶 B (PKB,也称为 AKT) 是细胞中 PI3K/AKT/mTOR 信号传导的核心,其功能对细胞生长、存活、分化和代谢很重要。AKT-IN-9 具有研究乳腺癌和前列腺癌的潜力 (摘自专利 WO2021185238A1,化合物 1)。

AKT-IN-9

AKT-IN-9 Chemical Structure

CAS No. : 2709045-53-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1)[1].

IC50 & Target

AKT[1]

分子量

452.98

Formula

C24H29ClN6O

CAS 号

2709045-53-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Xin Li, et al. Thickened dicyclic derivatives, their preparation methods and their application in medicine. Patent WO2021185238A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-10

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-10 

AKT-IN-10 是一种有效的 AKT 抑制剂。蛋白激酶 B (PKB,也称为 AKT) 是细胞中 PI3K/AKT/mTOR 信号传导的核心,其功能对细胞生长、存活、分化和代谢很重要。AKT-IN-10 具有研究乳腺癌和前列腺癌的潜力 (摘自专利 WO2021185238A1,化合物 4)。

AKT-IN-10

AKT-IN-10 Chemical Structure

CAS No. : 2709045-56-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4)[1].

IC50 & Target

AKT[1]

分子量

484.03

Formula

C26H34ClN5O2

CAS 号

2709045-56-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Xin Li, et al. Thickened dicyclic derivatives, their preparation methods and their application in medicine. Patent WO2021185238A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKT-IN-9

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AKT-IN-9 

AKT-IN-9 是一种有效的 AKT 抑制剂。蛋白激酶 B (PKB,也称为 AKT) 是细胞中 PI3K/AKT/mTOR 信号传导的核心,其功能对细胞生长、存活、分化和代谢很重要。AKT-IN-9 具有研究乳腺癌和前列腺癌的潜力 (摘自专利 WO2021185238A1,化合物 1)。

AKT-IN-9

AKT-IN-9 Chemical Structure

CAS No. : 2709045-53-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1)[1].

IC50 & Target

AKT[1]

分子量

452.98

Formula

C24H29ClN6O

CAS 号

2709045-53-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Xin Li, et al. Thickened dicyclic derivatives, their preparation methods and their application in medicine. Patent WO2021185238A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务